pre-IPO PHARMA

COMPANY OVERVIEW

Quell Therapeutics is a privately held biotechnology company with a vision to become a leading engineered TRegs cell therapy company. The company is developing next generation engineered T-regulatory (TReg) cell therapies for a range of solid organ transplant and autoimmune conditions.


LOCATION

  • London, , UK

  • THERAPEUTIC AREAS

  • Autoimmune Disease
  • Immunology
  • Inflammatory Disease
  • Oncology

  • WEBSITE

    https://quell-tx.com


    CAREER WEBSITE

    https://quell-tx.com/careers/


    SOCIAL MEDIA


    INVESTORS

    syncona syncona-partners


    PRESS RELEASES


    Apr 27, 2022

    Quell Therapeutics and Cellistic™ enter a strategic collaboration to develop an iPSC-derived allogeneic T-regulatory (Treg) cell therapy platform


    Jan 6, 2022

    Quell Therapeutics Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference


    Nov 29, 2021

    Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform


    Nov 29, 2021

    Jeito Capital co-leads $156 million oversubscribed Series B financing in Quell Therapeutics


    Oct 27, 2021

    Quell Therapeutics Granted CTA Approval to Begin First Clinical Trial with a Multi-modular Engineered Treg Cell Therapy


    For More Press Releases


    Google Analytics Alternative